Study to Evaluate the Safety and Immune Response of Two-Doses of Candidate Influenza Vaccine GSK 1557484A in Adults

Exclusion Criteria

• •Presence of significant acute or chronic, uncontrolled medical or psychiatric illness
• •Presence of evidence of substance abuse or of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.
• •Blood pressure abnormalities
• •Diagnosed with cancer, or treatment for cancer, within 3 years.
• •Persons with a history of cancer who are disease-free without treatment for 3 years or more are eligible.
• •Persons with a history of histologically-confirmed basal cell carcinoma of the skin successfully treated with local excision only are excepted and may enroll, but other histologic types of skin cancer are exclusionary.
• •Women who are disease-free 3 years or more after treatment for breast cancer and receiving long-term prophylactic tamoxifen are excepted and may enroll.
• •Presence of an oral temperature ≥ 37.8º C, or acute symptoms greater than "mild" severity on the scheduled date of first vaccination.
• •Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.
• •Receipt of cytotoxic or immunosuppressive drug within 6 months of study enrollment.
• •Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin.
• •Administration of any non-influenza vaccines within 30 days before study enrollment or during the study period.
• •Use of any investigational or non-registered product (drug or vaccine) or planned participation in another investigational study within 30 days prior to study enrollment, or during the study period.
• •Receipt of any immunoglobulins and/or any blood products within 3 months of study enrollment or planned administration of any of these products during the study period.
• •Any known or suspected allergy to any constituent of influenza vaccines.
• •Known pregnancy or a positive urine beta-human chorionic gonadotropin (ß-hCG) test result prior to dosing on Study Days 0 or 21.
• •Lactating or nursing.
• •Women of child bearing potential who lack a history of reliable contraceptive practices.
• •Known receipt of analgesic or antipyretic medication on the day of treatment